MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 328074 | Name: Reglitazar

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Reglitazar, also known as JTT-501; PNU-182716; PNU-716, FK-614; Reglixane, is a PPARɑ agonist and PPARγ agonist potentially for the treatment of diabetes. JTT-501 reverses hypertriglyceridemia in Zucker fatty and ventromedial hypothalamus-lesioned obese rats. JTT-501 rapidly stimulates glucose disposal rates by enhancing insulin signal transduction in skeletal muscle.JTT-501 improves insulin resistance in genetic and non-genetic insulin-resistant models.

Chemical Structure

Reglitazar
Reglitazar
CAS#170861-63-9

Theoretical Analysis

MedKoo Cat#: 328074

Name: Reglitazar

CAS#: 170861-63-9

Chemical Formula: C22H20N2O5

Exact Mass: 392.1372

Molecular Weight: 392.41

Elemental Analysis: C, 67.34; H, 5.14; N, 7.14; O, 20.39

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Reglitazar; JTT-501; PNU-182716; PNU-716; JTT501; PNU182716; PNU716; FK-614; FK614; Reglixane.
IUPAC/Chemical Name
4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)isoxazolidine-3,5-dione
InChi Key
QBQLYIISSRXYKL-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H20N2O5/c1-14-19(23-21(28-14)16-5-3-2-4-6-16)11-12-27-17-9-7-15(8-10-17)13-18-20(25)24-29-22(18)26/h2-10,18H,11-13H2,1H3,(H,24,25)
SMILES Code
O=C(C1CC2=CC=C(OCCC3=C(C)OC(C4=CC=CC=C4)=N3)C=C2)NOC1=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 392.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Guo L, Zhang L, Sun Y, Muskhelishvili L, Blann E, Dial S, Shi L, Schroth G, Dragan YP. Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. Mol Divers. 2006 Aug;10(3):349-60. PubMed PMID: 17031537. 2: Zhong CB, Zhu XJ, Liu ZR, Gao XP, Wang XC. [Design, synthesis and insulin-sensitizing activity of some peroxisome proliferator-activated gamma agonists]. Yao Xue Xue Bao. 2005 Feb;40(2):136-40. Chinese. PubMed PMID: 15875669. 3: Breda M, Basileo G, James CA. Simultaneous determination of JTT-501 and its main metabolite in human plasma by liquid chromatography-ionspray mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Aug 25;794(1):167-74. PubMed PMID: 12888209. 4: Yamanouchi T. [Chemical structures and pharmacological characteristics of novel non-thiazolidinedione insulin sensitizer (JTT-501, FK614)]. Nihon Rinsho. 2002 Sep;60 Suppl 9:573-7. Review. Japanese. PubMed PMID: 12387053. 5: Shinkai H. [The chemical structure and pharmacological properties of a novel isoxazolidinedione insulin sensitizer, JTT-501]. Nihon Rinsho. 2001 Nov;59(11):2207-10. Review. Japanese. PubMed PMID: 11712409. 6: Brunmair B, Gras F, Neschen S, Roden M, Wagner L, Waldhäusl W, Fürnsinn C. Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-gamma-mediated changes in gene expression. Diabetes. 2001 Oct;50(10):2309-15. PubMed PMID: 11574413. 7: Eto K, Ohya Y, Nakamura Y, Abe I, Fujishima M. Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle. Eur J Pharmacol. 2001 Jun 29;423(1):1-7. PubMed PMID: 11438300. 8: Tang Y, Osawa H, Onuma H, Hasegawa M, Nishimiya T, Ochi M, Makino H. Adipocyte-specific reduction of phosphodiesterase 3B gene expression and its restoration by JTT-501 in the obese, diabetic KKAy mouse. Eur J Endocrinol. 2001 Jul;145(1):93-9. PubMed PMID: 11415857. 9: Uchida K, Ogino K, Shimoyama M, Hisatome I, Shigemasa C. Acute hemodynamic effects of insulin-sensitizing agents in isolated perfused rat hearts. Eur J Pharmacol. 2000 Jul 14;400(1):113-9. PubMed PMID: 10913592. 10: Niwa M, Rashid S, Shum K, Mathoo JM, Chan O, Tchipashvili V, Kawamori R, Vranic M, Giacca A. Effect of JTT-501 on net hepatic glucose balance and peripheral glucose uptake in alloxan-induced diabetic dogs. Metabolism. 2000 Jul;49(7):862-7. PubMed PMID: 10909996. 11: Yamazaki Y, Osaka T, Murakami T, Inoue S. JTT-501, a new oral hypoglycemic agent, reverses hypertriglyceridemia in Zucker fatty and ventromedial hypothalamus-lesioned obese rats. Metabolism. 2000 May;49(5):574-8. PubMed PMID: 10831165. 12: Shibata T, Takeuchi S, Yokota S, Kakimoto K, Yonemori F, Wakitani K. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. Br J Pharmacol. 2000 Jun;130(3):495-504. PubMed PMID: 10821776; PubMed Central PMCID: PMC1572094. 13: Shibata T, Matsui K, Yonemori F, Wakitani K. Triglyceride-lowering effect of a novel insulin-sensitizing agent, JTT-501. Eur J Pharmacol. 1999 May 28;373(1):85-91. PubMed PMID: 10408254. 14: Kadowaki T. [Insulin-sensitizing agents]. Nihon Rinsho. 1999 Mar;57(3):688-94. Review. Japanese. PubMed PMID: 10199155. 15: Maegawa H, Obata T, Shibata T, Fujita T, Ugi S, Morino K, Nishio Y, Kojima H, Hidaka H, Haneda M, Yasuda H, Kikkawa R, Kashiwagi A. A new antidiabetic agent (JTT-501) rapidly stimulates glucose disposal rates by enhancing insulin signal transduction in skeletal muscle. Diabetologia. 1999 Feb;42(2):151-9. PubMed PMID: 10064094. 16: Shibata T, Matsui K, Nagao K, Shinkai H, Yonemori F, Wakitani K. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol. 1999 Jan 8;364(2-3):211-9. PubMed PMID: 9932726. 17: Shibata T, Matsui K, Yonemori F, Wakitani K. JTT-501, a novel oral antidiabetic agent, improves insulin resistance in genetic and non-genetic insulin-resistant models. Br J Pharmacol. 1998 Dec;125(8):1744-50. PubMed PMID: 9886766; PubMed Central PMCID: PMC1565761. 18: Shinkai H, Onogi S, Tanaka M, Shibata T, Iwao M, Wakitani K, Uchida I. Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents. J Med Chem. 1998 May 21;41(11):1927-33. PubMed PMID: 9599241. 19: Terasaki J, Anai M, Funaki M, Shibata T, Inukai K, Ogihara T, Ishihara H, Katagiri H, Onishi Y, Sakoda H, Fukushima Y, Yazaki Y, Kikuchi M, Oka Y, Asano T. Role of JTT-501, a new insulin sensitiser, in restoring impaired GLUT4 translocation in adipocytes of rats fed a high fat diet. Diabetologia. 1998 Apr;41(4):400-9. PubMed PMID: 9562343.

View History

Remiprostol

Remiprostol